跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NAT-ERIBULIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NAT-ERIBULIN
Authorized
STANDARD
NAT-ERIBULIN
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
8d41278d48b3eed3
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
8d41278d48b3eed3
Drug Approval Canada Name
NAT-ERIBULIN
Product Name
NAT-ERIBULIN
Status
Marketed
Status Date
2024-01-08
Original Market Date
2024-01-08
Din
02539136
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01XX41 ERIBULIN
Atc Name
l 01 xx 41
Aig Number
0153064001
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
ERIBULIN MESYLATE
0.5 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
8d41278d48b3eed3
Type
Standard
Back to Health Canada Approvals